Samsung Biologics launches all‑cash CHF 44.31 per share tender offer to acquire PolyPeptide, boosting its multi‑modality CDMO footprint

Samsung Biologics announced an all‑cash public tender offer for 100% of PolyPeptide at CHF 44.31 per share, representing an equity value of roughly CHF 1.46 billion. The acquisition expands Samsung Biologics’ peptide manufacturing capacity and broadens its multi‑modality service offering across the U.S., Europe and India, strengthening its position in the fast‑growing biologics CDMO market. Who is involved: Samsung Biologics (acquirer), PolyPeptide (target), PolyPeptide shareholders, and antitrust authorities in the United States and the European Union.. Likely next: The tender offer will remain open for a defined period after which shareholders may tender shares; closing is contingent upon customary conditions, including antitrust clearance in the US and EU.. Samsung Biologics has announced an all‑cash public tender offer for 100% of PolyPeptide at CHF 44.31 per share, valuing the target’s equity at approximately CHF 1.46 billion. The transaction is intended to add PolyPeptide’s peptide manufacturing sites in the United States, Europe and India to Samsung Biologics’ contract development and manufacturing organization (CDMO) platform, thereby expanding its multi‑modality capabilities. The deal is subject to standard closing conditions, including antitrust clearance in the US and EU, and will proceed once shareholders tender their shares and regulatory approvals are obtained. Sectors affected: biologics contract development and manufacturing (CDMO) peptide therapeutics manufacturing Regulatory implications: US Hart‑Scott‑Rodino Antitrust Improvements Act review EU Merger Regulation scrutiny Historical parallels: Lonza’s acquisition of Capsugel (2020) Thermo Fisher Scientific’s purchase of Patheon (2017)

Geographic Focus

Executive Summary

✦ Editor's Take · Objective

Timeline

Relationship Graph

Live Feed

Source Evidence

AI Insights

Entities

Social Pulse